ERBB2 and neoplasm: The confirmed objective response rate in DESTINY-Gastric06 was numerically lower than that observed in DESTINY-Gastric01, which may be attributable to multiple differences across the trials, including patient characteristics, prior use of HER2-directed therapies, disease burden, tumor size, and number of prior lines of therapy.